All In Biotech

Drug Trial Radar · NCT01930708

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

Last checked: Nov 20, 2026Latest source record: Mar 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,114

Actual

Start

Oct 31, 2013

Primary completion

Mar 31, 2016

Study completion Jan 9, 2020

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Aug 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period. The secondary objectives of this study in this population are to assess the impact of DMF over a 12-month period on participants -reported health-related quality of life (HRQoL) outcomes, additional clinical effectiveness outcomes, and health economics-related outcomes, and to characterize participants-reported adherence to DMF.

Conditions

  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis

Interventions

  • dimethyl fumarateDrug

    Administered as per the approved dosage in all countries where DMF has received marketing authorization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: 12 Months

Locations

90 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Innsbruck, Austria

  • Research Site

    Klagenfurt, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Sankt Pölten, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Villach, Austria

  • Research Site

    Bruges, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Melsbroek, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Victoria, British Columbia, Canada

  • Research Site

    Saint John's, New Brunswick, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Havířov, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Pardubice, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Nancy, France

  • Research Site

    Rouen, France

  • Research Site

    Strasbourg, Bas Rhin, France

  • Research Site

    Dijon, Cote dÝOr, France

  • Research Site

    Besançon, Doubs, France

  • Research Site

    Nîmes, Gard, France

  • Research Site

    Bordeaux, Gironde, France

  • Research Site

    Colmar, Haut Rhin, France

  • Research Site

    Toulouse, Haute Garonne, France

  • Research Site

    Limoges, Haute Vienne, France

  • Research Site

    Rennes, Ille Et Vilaine, France

  • Research Site

    Grenoble, Isere, France

  • Research Site

    Nantes, Loire Atlantique, France

  • Research Site

    Reims, Marne, France

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.